Key result
Residence in states with hepatitis A vaccination recommendations was associated with a higher seroprevalence of anti-HAV among U.S.-born children compared to non-vaccinating states.
Why the study?
Does residence in states with hepatitis A vaccination recommendations increase anti-HAV seroprevalence in the U.S. population?
Cross-Sectional (n=51,118)
Does residence in states with hepatitis A vaccination recommendations increase anti-HAV seroprevalence in the U.S. population?
The 1999 hepatitis A vaccination recommendations were associated with a significant increase in population immunity among children in states where vaccination was recommended.
Answers are grounded in this paper and cite their sources.
Supports association of recommendations with higher childhood seroprevalence; hypothesis-generating and requires prospective studies before informing policy.
OBJECTIVES: We described seroprevalence of antibody to hepatitis A virus (anti-HAV) in the United States during 1999-2006 and compared it with seroprevalence before the availability of vaccine. METHODS: We analyzed data from the 1988-1994 and 1999-2006 National Health and Nutrition Examination Survey (NHANES) to obtain estimates of anti-HAV seroprevalence for the U.S. household population. We grouped region of residence based on the 1999 Advisory Committee on Immunization Practices recommendations into 17 states with any recommendation (vaccinating) and 33 states without any recommendation (non-vaccinating). RESULTS: During 1999-2006, the overall seroprevalence of anti-HAV was 34.9% (95% confidence interval [CI] 33.1, 36.7). During 1999-2006, U.S.-born children living in vaccinating states (33.8%, 95% CI 26.2, 42.2) had a higher seroprevalence than children in non-vaccinating states (11.0%, 95% CI 9.4, 12.8; p < 0.001). Seroprevalence among children increased from 8.0% (95% CI 6.3, 10.1) during 1988-1994 to 20.2% (95% CI 16.0, 24.8) during 1999-2006 (p < 0.001). For U.S.-born children aged 6-19 years, the strongest factor associated with seroprevalence was residence in vaccinating states. Among U.S.-born adults aged > 19 years, the overall age-adjusted seroprevalence of anti-HAV was 29.9% (95% CI 28.3, 31.5) during 1999-2006, which was not significantly different from the seroprevalence during 1988-1994 (32.2%, 95% CI 30.1, 34.4). CONCLUSIONS: Increases in seroprevalence among children in vaccinating states suggest a positive effect of the 1999 vaccination recommendations.
No takes yet. Share an insight, caveat, or question.
Klevens et al. (2011) conducted a cross-sectional in Hepatitis A Virus (HAV) antibodies (n=51,118). Residence in vaccinating states vs. Residence in non-vaccinating states was evaluated on Anti-HAV seroprevalence in U.S.-born children aged 6-19 years (1999-2006) (OR 3.8, 95% CI 2.4-6.0, p=<0.001). Residence in states with hepatitis A vaccination recommendations was associated with a higher seroprevalence of anti-HAV among U.S.-born children compared to non-vaccinating states.
Synapse has enriched 10 related papers. Consider them for comparative context: